8-K filing — REPLIGEN CORP (RGEN)
Filed: 2026-09-15 AccNo: 0001628280-26-062043 Size: 138 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Stocks · News reference
Repligen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bioprocess Automation Market Poised for Robust Growth Through 2033, Driven by Demand for Efficient, Scalable Biomanufacturing
The global bioprocess automation market is projected to grow from USD 8.6 billion in 2025 to USD 22.2 billion by 2033, expanding at a CAGR of 12.8%. Growth is driven by rising demand for biologics, advances in AI and robotics, and pressure to improve manufacturing efficiency and regulatory compliance. Automation technologies enhance throughput, consistency, and cost-effectiveness while reducing errors and production time.
UBS Maintains Buy on Repligen, Raises Price Target to $225
UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $195 to $225.
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Novartis announced positive results from late-stage REMODEL-1/-2 studies showing remibrutinib, a BTK inhibitor, significantly reduced annualized relapse rates versus Aubagio in relapsing multiple sclerosis patients. The drug also reduced inflammatory brain lesions with a favorable safety profile. Novartis plans global regulatory filings and will present data at MSToronto2026. Shares gained 6% on the news.